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Parainfluenza virus type 5 (PIV5), formerly known as simian virus 5 (SV5), is a non-segmented negative strand RNA virus that offers several
advantages as a vaccine vector. PIV5 infects many cell types causing little cytopathic effect, it replicates in the cytoplasm of infected cells, and
does not have a DNA phase in its life cycle thus avoiding the possibility of introducing foreign genes into the host DNA genome. Importantly,
PIV5 can infect humans but it is not associated with any known human illness. PIV5 grows well in tissue culture cells, including Vero cells, which
have been approved for vaccine production, and the virus can be obtained easily from the media. To test the feasibility of using PIV5 as a live
vaccine vector, the hemagglutinin (HA) gene from influenza A virus strain A/Udorn/72 (H3N2) was inserted into the PIV5 genome as an extra
gene between the hemagglutinin-neuraminidase (HN) gene and the large (L) polymerase gene. Recombinant PIV5 containing the HA gene of
Udorn (rPIV5-H3) was recovered and it replicated similarly to wild type PIV5, both in vitro and in vivo. The HA protein expressed by rPIV5-H3-
infected cells was incorporated into the virions and addition of the HA gene did not increase virus virulence in mice. The efficacy of rPIV5-H3 as a
live vaccine was examined in 6-week-old BALB/c mice. The results show that a single dose inoculation provides broad and considerable
immunity against influenza A virus infection.
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PIV5, formerly known as simian virus 5 (SV5), is a non-
segmented negative strand RNA virus in the paramyxovirus
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Nucleocapsid protein (NP), phosphoprotein (P), V and large
RNA polymerase (L) proteins are important for transcription and
replication of the RNA genome. Several studies suggest that the
V protein has a role in evasion of host immune responses as well
as in regulating viral RNA synthesis (Didcock et al., 1999; He et
al., 2002; Lin and Lamb, 2000; Lin et al., 2005; Sun et al., 2004).
The fusion (F) glycoprotein mediates both virus to cell and cell to
cell fusion in a pH independent manner. The hemagglutinin-
neuraminidase (HN) glycoprotein, is the receptor binding protein
and its neuraminidase activity is important for virus release from
host cells (Schmitt et al., 1999; Yuan et al., 2005). The matrix (M)
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et al., 2005). The SH integral membrane protein may have an
important role in inhibiting TNF-α-mediated apoptosis (Lin et
al., 2003; Wilson et al., 2006).
Non-segmented negative strand RNA viruses (NNSVs) such
as PIV5 are potential viral vector candidates for vaccine
development. As compared to DNA viruses, the NNSVs are
potentially safer because they do not have a DNA phase in their
life cycles and most of them replicate in the cytoplasm, thus
avoiding unintended consequences from genetic modifications
of host cell DNA that may be associated with recombination or
insertion. In addition, as compared to positive strand RNA
viruses, the genome of NNSVs is stable. These characteristics
make NNSVs useful as potential vaccine vectors.
Despite the advantages of using NNSV as vaccine vectors,
only in recent years has it been possible to manipulate their RNA
genomes due to the development of methodologies for perform-
ing reverse genetics (Neumann et al., 2002; Schnell et al., 1994).
This has allowed for successful generation of recombinant NNSV
vectors that include vesicular stomatitis virus (VSV), human
parainfluenza virus 3 (hPIV3) and Newcastle disease virus
(NDV). VSV is a highly lytic NNSV which has been engineered
to express a hemagglutinin (HA) gene of influenza A virus. The
recombinant HA-VSV has been shown to provide a level of
immunity in mice challenged with influenza A virus (Roberts et
al., 1998). In addition, NDVhas been used to express the HAgene
of human (H1N1) influenza and the recombinant virus shown to
provide immunity against influenza virus challenge in mice
(Nakaya et al., 2001). Very recently, NDVwas used to express the
HA protein of avian (H5N1) influenza and this virus induces
potent protection against both influenza and NDV infection in
poultry (Park et al., 2006; Veits et al., 2006).
PIV5 infects a range of cell types including primary human
cells (Arimilli et al., 2006). Indeed, there has been no report of a
cell line that is resistant to PIV5 infection. Importantly, PIV5
causes very little cytopathic effect (CPE) in infected cells
(Choppin, 1964; Zakstelskaya et al., 1976). PIV5 also infects
most mammals including humans and is not associated with any
clinical disease with the exception of canine kennel cough (Cohn
et al., 1996; Cornwell et al., 1976; McCandlish et al., 1978). The
ability of PIV5 to infect a large spectrum of cells with little
cytopathic effect suggests that this virus could be used for gene
expression in a wide range of species to elicit a broad spectrum
immune response without associated inflammation and patho-
genicity. Moreover, the lack of CPE allows PIV5 grow in
common cell lines, including MDBK cells, for more than 40 days
while the virions are continually released into media at titers up to
8×108 PFU/ml (Choppin, 1964), providing an easy and cost
effective means for mass production of the vaccine vector.
In previous studies, it was shown that PIV5 could be readily
recovered from cloned DNA, and that a foreign gene encoding
green fluorescent protein (GFP) could be inserted into the PIV5
genome (rPIV5-GFP) with GFP expressed cytoplasmically (He
et al., 1997). Recombinant PIV5 containing GFP (rPIV5-GFP)
replicates to similar titers as wild type (wt) PIV5 and insertion of
the gene into the viral genome is stable. We tested the feasibility
of utilizing recombinant PIV5 as a vaccine vector by expressingthe HA gene of influenza A virus. We show that we can insert
the HA gene from influenza A/Udorn/72 (H3N2 subtype) virus
into the PIV5 genome at the gene junction between HN and L
genes, recover infectious recombinant PIV5 containing the HA
gene (rPIV5-H3), and that mice immunized with rPIV5-H3 are
protected from challenge with influenza virus.
Results
Generation of rPIV5-H3
The HA gene of influenza A virus (A/Udorn/72, H3N2
subtype) was inserted between the HN and L genes of PIV5 in a
plasmid (pBH311) containing the full length PIV5 genome as
previously described for the GFP gene (Fig. 1A) (He et al.,
1997). To ensure correct viral transcription initiation, termina-
tion and polyadenlyation of transcripts, the HA gene was
flanked with gene start (GS), intergenic sequences (I) and gene
end (GE) sequences from the junction region of the NP and V/P
genes which gives high level transcription (He and Lamb,
1999). Recovery of rPIV5-HA was performed as described by
He et al. (11) and recovery was as efficient as that of wild type
PIV5. The authenticity of the rescued virus as rPIV5-H3 was
confirmed by RT-PCR (Fig. 1A). Insertion of the HA gene
increases the expected size of RT-PCR fragment to 2.1 kb from
400 base pairs (bp) when using the specific primers that anneal
to the HN and L genes (Fig. 1A). This 2.1 kb fragment was
sequenced and found to match the input HA gene sequence
(data not shown). It is known that PIV5 infects human cells
(primary and established cell lines) (Arimilli et al., 2006). Thus
to examine expression of HA in human primary cells, cells from
human peripheral blood mononuclear cells (PBMC) were
infected with PIV5 and PIV5-H3. Virus gene expression was
detected in the human primary cells for both viruses (Fig. 1B).
Expression of HA on the surface of cells infected with
rPIV5-H3
Expression of the HA gene in cells infected with rPIV5-H3
was examined by using both immunofluorescence and immu-
noprecipitation techniques. rPIV5-H3-infected CV-1 cells were
stained with anti-HA antibody and anti-F antibody and surface
expression of both HA and F could be detected (Fig. 1C). Cell
surface-expressed F protein was also detected using an
F-specific mAb. Expression and cleavage of HA on the cell
surface were confirmed by treatment of cell surfaces with
trypsin. As shown in Fig. 1D, uncleaved HA0 could be cleaved
by addition of exogenous trypsin to HA1 and HA2. Immuno-
precipitation of the V/P proteins indicated that amounts of viral
proteins expressed were similar between wild type PIV5 and
rPIV5-H3 viruses.
Incorporation of HA into the rPIV5-H3 virion
To analyze the incorporation of HA into rPIV5-H3 virions,
the virus was grown in MDBK cells and purified, and
polypeptides were analyzed by SDS-PAGE. HA was observed
Fig. 1. Generation of rPIV5-H3 and expression of HA in virus-infected cells. (A) Generation of rPIV5-H3. HA gene was inserted between HN and L genes of PIV5.
The shaded area represents regions between two genes. It contains GE (gene end), I (intergenic) and GS (gene start) sequences which are important for RNA
transcription. A genomic nucleotide length divisible by six (the rule of six) was maintained. Oligomer BH195 that anneals to genome sense of HN gene was used for
reverse-transcription; oligomer BH196 that anneals to mRNA sense of L gene and oligomer BH195 were used for PCR. The PCR product was resolved in 1% agarose
gel. The DNA size markers are indicated. (B) Immunofluorescence of human primary cells infected with PIV5 and PIV5-H3. Cells obtained from primary human
PBMC cells (mostly macrophages) were infected with PIV5, PIV5-H3 or mock infection. At 2 days p.i., the cells on coverslips were fixed and treated with anti-NP
(red) and anti-V/P (green) antibodies. (C) Expression of HA in infected cells. CV-1 cells were infected by the rPIV5 or rPIV5-H3 and the cells were processed for
immunofluorescence or immunoprecipitation at 20 h p.i. CV-1 cells on coverslips were fixed and treated with anti-HA and anti-F antibodies as indicated. (D)
Expression of HA on cell surface. Infected CV-1 cells were labeled with 35S-Met and 35S-Cys for 2 h and lysed directly or treated with trypsin and then lysed. The
lysates were immunoprecipitated with antibodies against HA and the Vand P proteins of PIV5. Sizes of molecular weight marker and positions of V, P, HA0, HA1 and
HA2 are indicated.
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its identity confirmed by immunoblotting (data not shown).
Concomitantly, the amount of HN incorporated into rPIV5-H3was decreased as compared to the amount of HN incorporated
into wt PIV5. To eliminate the possibility that the HA protein
observed was associated with contaminating vesicles and
Fig. 2. Incorporation of HA into purified virions. rPIV5-H3 was purified as
described in the Material and Methods. (A) The purified virus polypeptides were
resolved using a 15% SDS-PAGE gel and the gel was stained with Commasie
blue. Positions of viral proteins are indicated. (B) The purified virions were
treated with anti-HA mAb and gold particle-labeled secondary antibody and
then examined by electron microscopy. Panels of different virions are indicated.
(For interpretation of the references to colour in this figure legend, the reader is
referred to the web version of this article.)
Fig. 3. Growth of rPIV5-H3 in vitro and in vivo. (A) Growth curve in vitro.
MDBK cells were infected at 10 PFU/cell. Media from the infected cells were
collected at 6 h intervals up to 48 h p.i. Titers of the media were examined using
plaque assay in BHK-21F cells. (B) Growth in vivo. BALB/c mice (15 in a
group) were infected with PIV5 or rPIV5-H3. Five mice per group were
sacrificed on days 4, 6 and 8 p.i. Titers of viruses in lung were determined by
plaque assay.
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using HA antibody and examined by electron microscopy. HA
labeling of virion was readily detected (Fig. 2B).
As PIV5 virions are pleomorphic with sizes ranging from 100
to 200 nm, we examined a large number of virions and found no
change in virion morphology or size associated with the
recombinant virus, indicating that the addition of 1700 nt into
the PIV5 genome did not alter virion morphology (data not
shown).
Growth of rPIV5-H3 in vitro and in vivo
To determine if insertion of the HA gene had any detrimental
effect on virus replication, single-step growth curves of wt PIV5
and rPIV5-H3 viruses were performed. MDBK cells were
infected with 10 plaque-forming units (PFU) per cell of rPIV5 or
rPIV5-H3 and supernatants were collected at 6 h intervals for up
to 48 h and virus quantified by plaque assay (Fig. 3). The growth
curve for rPIV5-H3 was very similar to that of wt virus. Both
viruses had similar initial growth kinetics and reached a plateau
at about 24 h post-infection (p.i.). Additionally, the plaque sizes
of the two viruses were comparable (data not shown).
To examine the growth of rPIV5-H3 in vivo, BALB/c mice
were inoculated intranasally (i.n.) with 106 PFU of PIV5 or
rPIV5-H3. Lungs of the infected animals were collected at 4, 6
and 8 days p.i., and virus titers in lungs were determined byusing plaque assays as described previously (He et al., 2002). It
was found that PIV5 replicated to higher titers than rPIV5-H3 at
4 days p.i. (Fig. 3B); however, the differences in virus titer
diminished over time, e.g. at 8 days p.i. both viruses had
approximately the same titers, i.e. ∼103 PFU.
Pathology of rPIV5-H3 in BALB/C mice
PIV5 infection does not cause known overt disease except
kennel cough in canines (Chatziandreou et al., 2004). Whether
PIV5 infection was pathogenic for mice and whether expression
of the HA gene could affect the pathogenicity of the virus in
mice have been determined. First, BALB/c mice were infected i.
n. with 106 PFU of rPIV5-H3 and the body weights of the
infected mice monitored daily. Infection of mice with rPIV5-H3
did not cause any detectable symptoms or weight loss compared
with mock (PBS)-inoculated mice (Fig. 4A). Second, to address
other parameters of pathology that may be associated with PIV5
or rPIV5-H3 infection, BALB/c mice were inoculated i.n. with
106 PFU of PIV5 or rPIV5-H3. At 4, 6 and 8 days p.i., the
animals were sacrificed and lung pathology examined by H&E
staining. At each sampling period, histopathology changes were
similar in character andmagnitude in the lung lobes of individual
Fig. 4. Pathology of PIV5 and rPIV5-H3 in BALB/c mice. (A) Weight loss. BALB/c mice (n=8) were infected with rPIV5-H3 (106 PFU in 50 μl PBS) or mock-
infected with PBS only. Body weights of the mice were recorded and graphed as percentage of the weight before inoculation. (B) Pathology of PIV5 in mice. BALB/c
mice (n=9) were infected with rPIV5-H3 or rPIV5 (106 PFU in 50 μl PBS). Animals were sacrificed on days 4, 6 and 8 p.i. and lungs were removed and fixed. Lungs
were sectioned, H&E stained and analyzed. For each animal, four major pulmonary changes (peribronchiolar infiltrations; perivascular infiltrations; parenchymal
infiltrations; subpleural infiltrations) were subjectively scored 0–3 with 0=no change and 3=greatest change and a total score determined. Means of the total scores for
each group are graphed and standard deviations are shown as error bars. Scores of the two groups (PIV5 vs. rPIV5-H3) were compared at each time point (day 4, 6 or 8)
by Student's t-test and all p values are less than 0.05. No statistically significant differences (p<0.05) between the two viruses were observed. (C) Weights of nude
mice injected with PIV5 or rPIV5-H3. Nude mice (14-week-old, n=10) were infected i.v. with PIV5 or PIV5-H3 (107 PFU) in 200 μl volume. Body weights of the
mice were recorded and graphed as percentage of the weight before inoculation. (D) Pathology scores of lung. The mice were sacrificed and organs (lung, heart, liver,
kidney and spleen) were sectioned for H&E staining. Pathology scores of lung were shown. 1=mild pathology; 2= intermediate pathology; 3=server pathology. Bar is
average score and the error bar represents the range. No statistically significant differences between two viruses were observed.
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lung histopathology generally was characterized by low-level
perivascular, peribronchiolar, subpleural, and scattered intra-
alveolar infiltrations that were predominantly lymphocytes.
Infiltrates contained a few plasma cells by day 8 p.i. and intra-
alveolar infiltrates were admixed with macrophages. Cellular
infiltrations increased over the time-course of infection by both
viruses, but were generally mild, and at each time period
examined, there was no statistically significant difference
(P≤0.05) between groups (Fig. 4B). However, as expected,
the means for each group did increase with time. The mild
cellular reaction suggested a progressive, localized immunolo-
gic response in the lung, apparently associated with PIV5 as
addition of the HA gene did not exacerbate the reaction. To
further confirm that rPIV5-H3 did not cause enhanced
pathogenicity, the pathogenicity of the viruses in nude mice
have been examined by injecting 107 PFU of each virus into the
tail vein. Neither PIV5 nor PIV5-H3 caused signs of illness orweight loss at either early or late time-points post-infection,
indicating that the viruses are not pathologic even in immune
deficient mice (Fig. 4C). Examination of the organs from the
mice infected with different viruses indicated that there was no
difference in pathological scoring between PIV5 and rPIV5-H3-
infected mice (Fig. 4D). While signs of infection were observed
as expected, there were no significant pathology detected in the
spleen, heart, liver or kidney (data not shown) and only verymild
patchy histeocytosis and very diffuse mixed inflammatory
infiltrates, predominantly histocytes with a microgranuloma,
were observed in lungs of some of the animals in both PIV5 and
rPIV5-H3-infected mice.
Immunity against influenza A virus infection in mice immunized
with rPIV5-H3
To examine the efficacy of rPIV5-H3 as a live vaccine
against influenza A virus infection, 6-week-old BALB/c mice
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BALB/c mice were i.n. vaccinated with 0, 102, 104 or 10 6 PFU
of rPIV5-H3 or rPIV5 viruses diluted in 50 μl PBS. Six weeks
after vaccination, the mice were challenged i.n. with 106 PFU of
influenza A virus strain WSN-H3. WSN-H3 is a 7+1
reassortant virus containing all of the genome segments from
A/WSN/33 virus except the HA segment, which is from
A/Udorn/72 (Jin et al., 1996). WSN-H3 was generated
through recombination of genomes between A/WSN/33
(WSN), which is mouse-adapted and highly pathogenic, and
Udorn, a human strain, which is not pathogenic in mice.
WSN-H3 contains 7 genomic segments of WSN and the HA
segment from Udorn (subtype H3). As noted, WSN-H3 is
pathogenic in the mouse, although not as pathogenic as the
parent strain, WSN. Following challenge, the mice were
weighed daily. As expected, body weights of vaccinated andFig. 5. Efficacy of rPIV5-H3 as a live vaccine vector. Six-week-old BALB/c mice
challenged i.n. with influenza Avirus, WSN-H3.Weights of the mice were monitored
mouse in the control group mice (n=4), i.e. weights of mock- (PBS) immunized mice
(n=8), 104 (C) (n=8) or 106 PFU (D) (n=8) of rPIV5-H3 and then challengedWSN-H
then challenged with WSN-H3. (F) Weights of individual PIV5-immunized mouse cunvaccinated mice not challenged with WSN-H3 were
similar. For the mice that were not vaccinated with rPIV5-
H3, but challenged with the 106 PFU of WSN-H3, three out
of four died by day 10 (Fig. 5A). The remaining mouse lost
more than 30% of its body weight and had not recovered by
day 12. A similar mortality rate was initially observed in the
mouse group vaccinated with a low dose (102 PFU) of rPIV5-
H3 and challenged with WSN-H3 in which four of the mice
died at days 5, 8, 10 and 11 pi (Fig. 5B). However, the
remaining 4 vaccinated mice recovered after 6 days after
losing up to 20% to 30% of their body weight. By day 12,
these mice regained their weight indicating that there was limited
protection even for the mice inoculated with the low dosage of
rPIV5-H3. The group of mice inoculated with 104 PFU of
rPIV5-H3 suffered moderate weight loss (up to about 25%) and
all of the mice survived. They also started to recover weight atwere immunized i.n. with PIV5-H3 or rPIV5. Six weeks p.i., the mice were
and graphed as percentage of body weight of the mice. (A) Weights of individual
challenged with WSN-H3. (B–D)Weights of individual immunized with 102 (B)
3. (E) Average weights of mice immunized with 104 and 106 PFU rPIV5-H3 and
hallenged with WSN-H3 (n=8).
Fig. 7. Antibodies in rPIV5-H3 immunized mice. BALB/c mice (n=10 per
group) were immunized with rPIV5, rPIV5-H3 or WSN-H3 and 19 days later,
serum was collected for serum antibody analysis. (A) Influenza virus-specific
antibody titers were measured in serum samples using an IgG+IgM-specific
ELISA as described in Materials and methods; (B) influenza A WSN-H3
neutralizing antibody titers were measured in serum samples by virus
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of rPIV5-H3 had the lowest weight loss following challenge and
all animals survived challenge (Fig. 5D). To confirm HA-
specific immunity in mice vaccinated with rPIV5-H3, a group of
mice were vaccinated i.n. with wild type rPIV5 alone and
similarly challenged with WSN-H3 (Fig. 5F). As expected,
rPIV5 alone did not provide immunity against influenza Avirus
challenge. Two of themice died at days 8 and 10, and the rest still
were suffering from weight loss up to day 12.
Influenza virus titers in the lungs of rPIV5-H3 inoculated mice
To further confirm protection associated with rPIV5-H3
vaccination, WSN-H3 titers in the lungs of infected mice were
determined by plaque assay. Animals from each immunization
group were sacrificed at days 4 and 7 post-challenge. The
results show that vaccination with rPIV5-H3 provided protec-
tion from influenza A virus challenge, as indicated by the
significant differences between PIV5 and rPIV5-H3 immunized
groups (Fig. 6A, P<0.001, ANOVA). Similar to WSN-H3
immunized mice, rPIV5-H3 vaccinated mice showed reductions
in lung virus titers and exhibited more rapid clearance of virus
compared to rPIV5-vaccinated mice. While all of the PIV5-
immunized mice still had some virus burden on day 7 p.i., the
rPIV5-H3 mice had begun to clear the infection on day 4 (1/5
mice were virus-free) and all were clear of virus by day 7 (Fig.
6B). Thus, immunization with PIV5 virus expressing theFig. 6. Reduction in influenza virus lung titer by rPIV5-H3 immunization.
BALB/c mice (n=10 per group) were immunized with rPIV5, rPIV5-H3 or
WSN-H3 (sub-lethal dosage, 103 PFU) and 29 days later, challenged with 106
PFU WSN-H3. Mice (n=4 or 5 per day per group) were sacrificed on day 4 (A)
and day 7 (B) post-challenge and lung virus titers were measured by plaque
assay. Data are presented as average PFU/lung±SEM. The number in
parenthesis indicates the number of samples with detectable virus. The limit
of detection was 20 PFU/lung.
neutralizing assay described in Materials and methods.influenza HA is sufficient to provide immunity that is
comparable to that induced by influenza virus.
Anti-influenza virus antibody production in mice
To investigate the level of the antibody responses in
vaccinated mice, sera were collected from mice vaccinated
with rPIV5-H3, PIV5, as well as from mice infected i.n. with a
sub-lethal dose of WSN-H3-inoculated (Fig. 7). Total and
neutralizing antibody levels against WSN (H1N1) andWSN-H3
(H3N1) were determined by ELISA against WSN. As predicted,
mice vaccinated with rPIV5 inoculation did not produce any
detectable amount of antibody against WSN since rPIV5 does
not express any WSN genes. In contrast, mice vaccinated with
rPIV5-H3 did produce high titers of antibody against WSN-H3,
presumably specific for the H3 protein (Fig. 7A). The generation
of neutralizing antibodies induced by rPIV5 or rPIV5-H3
vaccination was also examined. The results show that while
PIV5 inoculation did not produce anti-WSN-H3 neutralizing
antibodies, rPIV5-H3 inoculation produced a substantial
neutralizing antibody response against WSN-H3 that was
comparable to WSN-H3 infection (Fig. 7B). Higher antibody
titers observed in sub-lethal WSN-H3 inoculated mice may be
attributed to antibodies against other influenza virus proteins
such as NA and M2. It is known that immunization with live
influenza virus induces antibody and cellular immune
responses to not only HA, but also other influenza antigens
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contribute to protection and in some cases are sufficient to
protect against virus challenge (reviewed in Epstein, 2003).
Discussion
The development of reverse genetics technology for the
recovery of NNSVs from their cDNAs, has permitted the
expression of many foreign genes using these viruses (Bukreyev
et al., 2005; Palese et al., 1996; Park et al., 2006; Pekosz et al.,
1999; Roberts and Rose, 1998; Veits et al., 2006). Here we
recovered PIV5-H3, which contains an HA gene from influenza
A/Udorn/72 virus inserted between the HN and L genes of PIV5.
rPIV5-H3 was viable and the insertion of the HA gene appeared
to be stable and the virus grew well in tissue culture cells. A
single dose inoculation of the rPIV5-H3 provided immunity to
mice against influenza virus infection.
The HA protein was incorporated into PIV5 virions despite
the absence of specific PIV5 sequences that may be important
for incorporation into virions such as PIV5-specific cytoplasmic
tails. The HA protein was detected in purified virions by both
SDS-PAGE and electron microscopy (Fig. 2). Additionally, the
amount of HN incorporated into rPIV5-H3 virions was reduced
compared to rPIV5. It is perhaps surprising that HN was not
preferentially incorporated into virions over HA. The efficient
release of PIV5 from infected cells requires the cytoplasmic tail
of HN (Schmitt et al., 1999) and it is thought that the cytoplasmic
tail of HN is important for formation of budding virus and/or
pulling viral components into virions. Despite having a
cytoplasmic tail dissimilar to the HN, HA was incorporated
into the PIV5 virions and presumably filled space at the expense
of HN.
A single dose inoculation of rPIV5-H3 provided immunity to
mice against influenza virus infection. The gradient of protection
provided by the virus indicates that effective immunity was
dependent on the dosage of the virus used and the protection was
provided by rPIV5-H3 inoculation but not by rPIV5. Although
the effectiveness of rPIV5-H3 in preventing death by influenza
Avirus infection is evident, all mice lost body weight, indicating
that protection is not optimal. This is partially due to the handling
of mice as even mock inoculated and mock challenged mice
suffered about 5%weight loss. To increase potency of rPIV5-H3
against influenza virus challenge, one possible remedy is to use
multiple inoculations (i.e. prime and boost) instead of a single
immunization prior to challenge. Alternatively, it may be
possible to increase expression of HA by inserting the HA
gene closer to the leader sequence of PIV5, the only de facto
promoter of PIV5. Negative stranded RNAviruses such as PIV5
initiate transcription from the 3′ end leader sequence, and
transcription levels of the viral genes are affected by the distance
of the gene from the leader sequence (Tokusumi et al., 2002). For
example, the NP gene of PIV5, which is proximal to the leader
sequence is the most abundantly transcribed, whereas the L
gene, which is distal to the leader sequence is least transcribed.
To increase the expression level of the HA gene, the HA gene
can be inserted immediately downstream of the leader sequence
and upstream of the NP gene.Safety is a paramount concern for vaccine development.
Expression of a foreign glycoprotein has the potential to expand
the host range beyond the original virus, therefore creating a
potential safety hazard. However, because PIV5 already infects
all cell types that have been tested, it is less likely that adding an
additional receptor-binding gene to its genome will change its
tropism. PIV5 encodes two major glycoproteins F and HN that
are important for PIV5 entry. The PIV5 F protein promotes
virus to cell fusion at the plasma membrane independent of pH.
In some cells, F alone is sufficient to promote cell-to-cell fusion
without PIV5’s receptor binding protein, HN (Paterson et al.,
2000). The HN protein of PIV5 mediates virus attachment by
binding to sialic acid, which is added to surface proteins post-
translationally. Unlike influenza virus protein, the HN protein of
PIV5 has no preference as to what kind of sialic acid it binds.
For example, PIV5 may infect primary chicken cells (Peluso et
al., 1977), which has mainly N-acetylneuraminic acid α 2,3-
galactose (NeuAcα2,3Gal) and may infect human cells (Lamb
and Kolakofsky, 2001), which has mainly NeuAcα2,6Gal (Ito
et al., 1997). Thus, it is unlikely that expressing influenza HA
will expand the host range of PIV5. Nevertheless, to address the
concern that enhanced pathogenicity may be caused by PIV5-
H3, we examined the pathogenicity of the viruses in nude mice
by injecting 107 PFU of each virus into the tail vein. Neither
PIV5 nor PIV5-H3 caused signs of illness or weight loss at
either early or late time-points post-infection, indicating that the
viruses are not pathological even in immune deficient mice (Fig.
4C). Examination of organs of the mice indicated that there was
no difference in pathological scoring between PIV5 and rPIV5-
H3-infected mice (Fig. 4D). Thus, as expected, insertion of the
HA gene into PIV5 genome did not cause increased
pathogenicity in mice. In the event that expressing a functional
HA is a concern, a mutant HA without HA1/HA2 cleavage site
can be used for influenza virus vaccine development.
Unlike icosahedral viruses, PIV5 virions have many forms
and shapes. This pleomorphic virion structure provides
flexibility to accommodate changes in sizes of PIV5’s genome.
This is an advantage for insertion of foreign genes as the
changes to the viral genome will probably not be tightly
restricted by the virion structure. While we do not know the
upper limit for the size of insertion in PIV5, in our hands,
insertion of 1700 nt, an increase of about 11% of genome size,
does not affect virus growth or integrity of virions. We have
now inserted and expressed a gene as large as 2.3 kb into PIV5
genome without difficulty (data not shown).
The origin and natural host of PIV5 is not clear. PIV5was first
isolated from monkey cells as a contaminant in 1956, hence the
original name SV5 (Hull et al., 1956). However, subsequent
serological testing of monkeys in the wild indicated no exposure
to this virus. In contrast, monkeys in captivity at an animal
facility rapidly sero-converted, suggesting they contacted the
virus in captivity (Atoynatan and Hsiung, 1969; Tribe, 1966).
Thus, considerable evidence indicates that PIV5 is not a simian
virus. PIV5 dose cause kennel cough in canines (Azetaka
and Konishi, 1988; Binn et al., 1967; Cornwell et al., 1976;
McCandlish et al., 1978; Rosenberg et al., 1971) and killed
PIV5 is a component of the commercial vaccine “Vanguard”
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vaccine. There is no convincing evidence that PIV5 causes
diseases in humans, despite much speculation in the 1970s
that PIV5 might be associated with a number of illnesses
including multiple sclerosis (MS), subacute sclerosing
panencepalitis (SSPE), Creutzfeldt-Jakob disease (CJD),
pemphigus, athero-sclerosis, Paget’s disease, hepatitis and
the common cold. Subsequent studies have ruled out PIV5 as
the etiological agent for these diseases (Chatziandreou et al.,
2004; Hsiung, 1972; Vandvik and Norrby, 1989). In
retrospect, two possible explanations exist for why PIV5
may have been linked to these diseases. One reason is based
on the conditions used for virus isolation in the human
studies, i.e. the labs used monkey cell lines which can be
persistently infected with PIV5, and these cells often show
no detectable cytopathic effects (Chatziandreou et al., 2004;
Hsiung, 1972). Another reason is that there is known antigen
cross-reactivity of PIV5 to ubiquitous paramyxoviruses such
as human parainfluenza virus 2 and mumps virus, which are
closely related to PIV5 and have almost 100% exposure in
human population (Komada et al., 1991; Randall and Young,
1988; Tsurudome et al., 1989). Given the possibility of PIV5
antigen cross-reactivity, it may be a concern to use PIV5 as a
vaccine vector. However, there is no indication from studies
in mice that antibodies can prevent PIV5 infection (Young et
al., 1990). As shown in Fig. 1B and others (Arimilli et al.,
2006), PIV5 can infect human primary cells, suggesting that
it is likely that PIV5 can infect humans.
While live virus vectors hold great promise, there are many
potential pitfalls, as has been demonstrated in studies using the
two most studied virus vectors: adenovirus and VSV. For
instance, adenovirus is a DNAvirus and thus has the potential to
integrate its genome. An additional problem is that there is a
very high incidence of adenovirus sera-positive people. Also, a
patient in a clinical trial died as a result of being treated with a
high dose adenovirus-based gene vector. The other viral vector
noted, VSV, is neurotrophic, thus its potential impact on
immune comprised patients is of an important concern.
Nonetheless, it is important to explore the potential use of
these viral vectors due to the many advantages of live virus
vectors over alternative vaccination strategies. As an RNAvirus
that infects respiratory epithelium, PIV5 offers an important
alternative vector with properties that make it worthy of special
consideration and further study, especially for developing an
influenza virus vaccine. Thus, although several NNSVs have
been used previously to express foreign viral antigens and to
protect mice for virus challenge, PIV5 offers an interesting
alternative vector with properties that make it worthy of special
consideration and further study.
Materials and methods
Plasmid construction and RT-PCR
HA gene from pTF7.5-HA was amplified by PCR using
oligomers BH291 (5′-ATTTCCTAGGTAATTTTTAAGAAA-
AAAACGATAGGACCGAACCTATCGATGCCGGCAAA-CATGAAGACTATCATTGCTTTG-3′) and BH292 (5′-
AAATTTGCATGCCATGGCCTAGGATATTCAAATG-
CAAATGTTGCACCT-3′). The PCR fragment was inserted
into HincII site of pGEM2 (Promega) to generate pBH374. The
coding region of HA gene in pBH374 was sequenced and found
to be identical to the HA gene in pTF7.5-HA. The HA gene was
excised out of the plasmid by digestion with ClaI and NcoI. The
fragment was then filled-in by the Klenow fragment and
inserted into filled-in NotI site of a plasmid (pBH311) (He et al.,
1997) which contains a GFP gene between the HN and L genes
in PIV5 genome to generate pBH412 which contains the PIV5
genome with the HA gene as an extra gene. Standard protocols
of molecular cloning were followed. Oligomers were purchased
from Macromolecular Resources (Colorado State University).
All sequences of the plasmids are on file and available on
request. Plasmids pTF7.5-HA, pT7-L, pT7-P and pT7-NP were
described before (He et al., 1997; Murphy and Parks, 1997).
To sequence the viral RNA genome, total RNA from CV-1
cells infected by virus in 6 cm plate was purified using RNeasy
kit (Qiagen®) according to the manufacture’s instruction. 19 μl
out of 50 μl RNAwas used with 20 ng of oligomer BH195 (5′-
TTCAGATTGTCCCATTTATCCGTCAGG-3′) for cDNA
synthesis at 37 °C for 1 h in a total volume of 40 μl. 10 μl of
cDNA was used in PCR with oligomers BH195 and BH196
(TGTAATGGACCTAAATCGTCAAGGTCG-3′). The PCR
products were resolved in 1% agarose gel.
Viruses and cells
Virus recovery was carried out as described before (He et al.,
1997). 5 μg of plasmid pBH412 which contains a PIV5 genome
with HA gene insertion was transfected with 3 μg of pT7-L,
0.2 μg of pT7-P and 2 μg of pT7-NP into A549 cells in 6-well
plates which were infected with the modified vaccinia virus
Ankara strain (MVA) containing a bacteriophage T7 RNA
polymerase gene for 1 h. Transfection media were changed to
DMEM containing 2% fetal calf serum (FCS) 24 h post
transfection. Virus released into the media was amplified in CV-
1 cells. Recovery of virus is indicated by syncytia formation in
BHK 21F cells on incubation with the media from the CV-1
cells. The virus was then purified as a single plaque from BHK
21F cells. Human primary cells were obtained from PBMC. The
human primary cells (mostly macrophages) from PBMCs were
prepared as described (Lee et al., 2001) and were seeded in 6-
well plate with coverslips for 6 days before used for infection.
Viruses were grown in MDBK cells for 5 to 7 days using
DMEM containing 2% FCS until their hema-absorption titers
plateaued. Media were collected and pelleted at 3000 rpm using
a Sorvall tabletop centrifuge for 10 min. BSAwas added to the
cleared supernatant to a final concentration of 1%. The virus
stock was quickly frozen in dry ice and stored at −70 °C. To
purify the viruses, viruses in the cleared supernatant were
pelleted in a Beckman ultracentrifuge Type 45Ti rotor at
19,000 rpm for 1 h. The pellet was then resuspended in NTE
buffer and loaded onto 15% to 60% sucrose gradient and
centrifuged in a SW 41Ti rotor for 2 h at 24,000 rpm. The virus
band was collected and virus was pelleted in a Type 70Ti rotor
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were determined by plaque assay on BHK-21F cells as
previously described (He et al., 1997).
MDBK cells, A549 cells and CV-1 cells were cultured in
DMEM with 10% FCS. BHK-21F cells were grown in DMEM
with 10% FCS and 10% tryptone phosphatase broth.
Immunoprecipitation of polypeptides
CV-1 cells in 6 cm plates were infected with rPIV5 and
rPIV5-H3 at a m.o.i. of about 5 pfu/cell and labeled with
100 μCi/ml 35S-Met and 35S-Cys 20 h p.i. (Paterson and Lamb,
1993). Half of the plates of CV-1 cells were treated with
0.01 mg/ml L-(tosylamido-2-phenyl) ethyl chloromethyl ketone
(TPCK)-treated trypsin for 1 h before the cells were lysed in
RIPA buffer (Paterson and Lamb, 1993). Lysates were
immunoprecipitated using mAb Pk specific for a shared region
of the V and P proteins and rabbit polyclonal antibody specific
for Udorn HA protein. Polypeptides were analyzed by 10%
SDS-PAGE and their radioactivity was detected using a Fuji
BioImager 1000.
Fluorescence and electron microscopy
CV-1 cells were grown on glass cover slips and infected with
rPIV5 or rPIV5-H3 at a m.o.i. of about 5 PFU/cell. At 20 h p.i.,
the infected cells were washed with PBS and then fixed with
1% formaldehyde for 10 min at room temperature. The cells
were washed three times with PBS and incubated for 30 min
with 1:500 dilution of antibodies against PIV5 F or HA. The
cells were washed extensively to remove unbound antibodies
and secondary antibodies labeled FITC were added for
30 min. The cells were further washed and placed on slides.
Fluorescence was examined using a Zeiss 410 confocal
microscope.
To examine HA in virions, purified virions were absorbed
onto parlodion-coated nickel grids for 30 s. Grids were floated
on a drop of Tris-buffered saline (TBS), pH 7.4 for 5 min, after
which they were incubated by floating on drops of 3%
ovalbumin in TBS for 1 h with HA-specific mouse mAb
ascites fluid 6D/1 diluted 1:300 in 1% ovalbumin in TBS.
Following three successive washes with TBS for 10 min each,
samples were incubated for 1 h with goat anti-mouse IgG
coupled to 10 nm gold particles diluted 1:10 in 1% ovalbumin in
TBS. Grids were washed in TBS as above and finally stained
with 2% phosphotungsic acid, pH 6.6. Before viewing, a thin
layer of carbon was evaporated over the grids for stability. The
grids were then examined using JEOL 1230 transmission
electron microscope (JEOL, Tokyo, Japan).
Virus titers in vivo and pathology of infection with PIV5 or
rPIV5-H3
Six-week-old BALB/c mice were first anesthetized with
Avertin i.p. and then infected intranasally (i.n.) with 106 PFU of
PIV5 or rPIV5-H3 in 50 μl PBS. At various times post-
infection, mice were euthanized and lungs collected for eitherlung virus titer or histopathologic analysis. For virus titers,
lungs were homogenized in 1 ml PBS and the homogenates
cleared by centrifugation. Cleared homogenates were serially
diluted and virus titers determined by plaque assay on BHK-21F
cells (He et al., 1997). For histopathology, lungs were perfused
with 10% buffered formalin via the trachea and then placed in
formalin for fixation. Sections of all lung lobes were embedded
in paraffin, sectioned at 3 μm, stained with hematoxylin and
eosin, and examined by light microscopy. For each animal, four
major pulmonary changes (peribronchiolar infiltrations; peri-
vascular infiltrations; parenchymal infiltrations; subpleural
infiltrations) were subjectively scored 0–3 with 0=no change
and 3=greatest change and a total score determined. For
pathology studies in nude mice, 107 PFU of each virus in a
200 μl volume was injected into the tail veins of nude mice. The
mice were weighed and sacrificed at 3, 7 and 14 days post
injection. The organs of the mice (lung, heart, liver, kidney and
spleen) were sectioned and processed for H&E staining.
Influenza A virus challenge experiments
Six-week-old BALB/c mice were first anesthetized and then
inoculated intranasally by dropping 50 μl PBS containing 0,
102, 104 or 10 6 PFU of viruses. Six weeks later, the mice were
inoculated intranasally with 50 μl PBS containing 106 PFU of
an influenza virus 7+1 reassortant WSN-H3 that contains all
segments from WSN strain except the HA segment which is
derived from A/Udorn/72. Body weights of the mice were
recorded everyday thereafter.
Antibody measurement
Influenza virus-specific serum antibody titers were mea-
sured using an IgG+IgM ELISA. Enzyme immunoassay plates
(Corning Costar, Inc.) were coated with 50 μl/well of WSN or
WSN-H3 containing approximately 105 PFU of virus. Viruses
were UV inactivated and the plates washed. The wells were
blocked with 200 μl/well Starting Block Buffer (Pierce, Inc.)
twice for 1 min. After washing, dilutions of sera were added
(50 μl/well) and incubated at room temperature for 2 h. Plates
were washed and 100 μl/well of a 1:1000 dilution of alkaline
phosphate-labeled rat goat-mouse IgG+IgM, IgG2a, IgG2b
and/or IgA (KPL, Inc.) was added. After incubation for 1 h at
room temperature, the plates were washed, 100 μl/well pNPP
phosphatase substrate (KPL, Inc.) was added, and the
enzymatic reaction was allowed to develop at room tempera-
ture. O.D. was measured at 405 nm on a BioTek plate reader.
The ELISA titer was the lowest serum dilution with an OD 2
standard deviations above the OD of the same dilution of naïve
serum.
Influenza neutralizing antibody titers were measured in
serum samples by virus neutralizing assay. Sera were serially
diluted in 50 μl DMEM+5% FBS. 2000 TCID50 of WSN-H3
virus was added to diluted sera and incubated for 60 min at
37 °C. Serum and virus were added to 96-well microtiter plates
containing 80–90% confluent MDCK cells and incubated
overnight at 37 °C. The wells were washed with PBS and the
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treated trypsin (Worthington) and incubated for 4 days at 37 °C.
Individual wells were scored for CPE and supernatants assayed
for virus by hemagglutination of chicken red blood cells
(cRBCs). In brief, fresh cRBCs were washed in Alsevier’s
solution, counted and resuspended in PBS at a final concentra-
tion of 0.5%. In a round-bottom, 96-well microtiter plate 50 μl
of 0.5% cRBCs was added to 50 μl of culture supernatant from
the virus neutralization, MDCK plate. Plates were tapped to
gently mix the cells and supernatants. The plates were incubated
at 4 °C for 1 h and scored for hemagglutination. The absence of
hemagglutination indicated a lack of infectious virus in the
neutralization assay, indicating the presence of influenza-
neutralizing antibodies in the serum samples. The neutralizing
titer was the lowest serum dilution neutralizing 2000 TCID50 of
virus.
Statistical analysis
Lung virus titers were compared using one-way ANOVA
statistical analysis on log-transformed data, followed by
pairwise multiple comparison using the Holm–Sidak method.
Lung histology scores were compared by Student’s t-test. All
statistical analysis was done with SigmaStat Software v3.11
(Systat Software, Point Richmond, CA).
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